Incannex Healthcare Investor Relations Material
Latest events
Q3 2025
15 May, 2025
Q2 2025
14 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Incannex Healthcare Inc
Access all reports
Incannex Healthcare Inc. is a clinical-stage pharmaceutical company focused on developing medicinal cannabis and psychedelic pharmaceutical products. The company is engaged in the research, development, and commercialization of therapies aimed at addressing a range of medical conditions. These include obstructive sleep apnea (OSA), traumatic brain injury (TBI), lung inflammation, rheumatoid arthritis, inflammatory bowel disease, anxiety, addiction, and chronic pain. Incannex Healthcare's product portfolio consists of both cannabinoid-based formulations and novel psychedelic therapies, which are in various stages of clinical development. The company is headquartered in Sydney, Australia, and its shares are listed on the NASDAQ.
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
IXHL
Country
🇺🇸 United States